Ionis Pharmaceuticals (IONS) News
NASDAQ: IONSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
45.28+1.98 (+4.57%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
IONS news summary
We found 5 recent headlines mentioning Ionis Pharmaceuticals (IONS): 2 in the past week and 4 in the past 30 days, most often from Nasdaq. For price context, IONS is up 4.57% at $45.28. The most recent story, "Alnylam vs. Ionis: Here's the Better Bad-News Buy", was published by Nasdaq on Oct 10, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Ionis Pharmaceuticals headlines
- Alnylam vs. Ionis: Here's the Better Bad-News BuyKey PointsAlnylam cut its full-year revenue guidance due to slower-than-expected sales for Amvuttra.NasdaqPFE, IONS, ALNY, AZN
- Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen DealNVS gains global rights to Abogen's ABO2203, expanding its RNA therapeutics push with a potential new approach to B-cell-mediated autoimmune diseases.NasdaqNVS, IONS, ACIU, PGEN
- Ionis Delivers Positive Late-Stage Results for Two Partnered DrugsIONS posts positive phase III results for two partnered drugs, with ulefnersen meeting its ALS endpoint and sefaxersen cutting proteinuria.NasdaqIONS, AZN, NVS
- NVS Gets Positive CHMP Opinion for Cosentyx for Another IndicationNVS' Cosentyx wins a positive EU opinion for PMR, backed by late-stage data, potentially expanding its use beyond existing inflammatory conditions.NasdaqNVS, RGEN, ANIK, IONS
- Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals(RTTNews) - This week's biotech roundup saw a flurry of FDA and EU approvals across neurology, oncology, cardiology, and rare diseases, alongside new partnerships, trial readouts, and restructuring…NasdaqAPVO, ASND, AZN, BIIB